在接受抗IL5/IL5R治疗的真实队列中对FEOS评分和超级应答者标准的评估。 - Suppr

Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R.

作者信息

Laorden Daniel, Zamarrón Ester, Romero David, Domínguez-Ortega Javier, Villamañán Elena, Losantos Itsaso, Gayá Francisco, Quirce Santiago, Álvarez-Sala Rodolfo

机构信息

Department of Pneumology, Hospital La Paz, Universidad Autónoma de Madrid, IdiPAZ, and CIBER of Respiratory Diseases, Madrid, Spain.

出版信息

Respir Med. 2023 May;211:107216. doi: 10.1016/j.rmed.2023.107216. Epub 2023 Mar 21.

DOI:10.1016/j.rmed.2023.107216

PMID:36958514

Abstract

摘要

相似文献

Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R.在接受抗IL5/IL5R治疗的真实队列中对FEOS评分和超级应答者标准的评估。

Respir Med. 2023 May;211:107216. doi: 10.1016/j.rmed.2023.107216. Epub 2023 Mar 21.

Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.在重度哮喘患者的真实队列中，使用不同标准比较奥马珠单抗和抗IL-5/IL-5R的长期反应与缓解情况。

Arch Bronconeumol. 2024 Jan;60(1):23-32. doi: 10.1016/j.arbres.2023.11.011. Epub 2023 Nov 22.

Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study.靶向白细胞介素 5/白细胞介素 5 受体的生物制剂诱导的重度哮喘缓解：一项多中心真实世界研究的结果。

Int J Mol Sci. 2023 Jan 27;24(3):2455. doi: 10.3390/ijms24032455.

Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis.抗 IL-5、抗 IL-5R、抗 IL-13 疗法对哮喘恶化的影响：网络荟萃分析。

Lung. 2020 Feb;198(1):95-103. doi: 10.1007/s00408-019-00310-8. Epub 2020 Jan 1.

A comparison of the impact of anti-IL5/5r therapies in allergic versus non-allergic patients with severe eosinophilic asthma in a real-life setting.在现实环境中，抗IL5/5R疗法对重度嗜酸性粒细胞性哮喘的过敏患者与非过敏患者的影响比较。

J Asthma. 2025 Feb;62(2):319-327. doi: 10.1080/02770903.2024.2400607. Epub 2024 Sep 14.

Correspondence regarding the paper "Laorden D, Zamarrón E, Romero D, Domínguez-Ortega J, Villamañán E, Losantos I, Gayá F, Quirce S, Álvarez-Sala R. Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R. Respir. Med. 2023; 211: 107216".关于论文“Laorden D, Zamarrón E, Romero D, Domínguez-Ortega J, Villamañán E, Losantos I, Gayá F, Quirce S, Álvarez-Sala R. 抗IL5/IL5R治疗的真实队列中FEOS评分和超级应答者标准的评估。《呼吸医学》。2023年；211: 107216”的通信

Respir Med. 2023 Aug;214:107280. doi: 10.1016/j.rmed.2023.107280. Epub 2023 May 10.

Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series.重度哮喘患者接受IL5/IL5R靶向治疗后呼出气一氧化氮水平升高：病例系列

J Asthma Allergy. 2022 May 19;15:691-701. doi: 10.2147/JAA.S358877. eCollection 2022.

Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.真实世界中贝那鲁肽、度普利尤单抗、美泊利单抗和瑞利珠单抗治疗严重哮喘的疗效：系统评价和荟萃分析。

Clin Exp Allergy. 2022 May;52(5):616-627. doi: 10.1111/cea.14112. Epub 2022 Mar 9.

Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.严重哮喘患者的上下气道炎症：精准生物治疗的指导。

Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620965151. doi: 10.1177/1753466620965151.

Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.针对白细胞介素-5 信号通路的抗体作为严重嗜酸性粒细胞性哮喘患者的附加治疗药物：皮下给予美泊利珠单抗和贝那利珠单抗的作用机制、疗效和安全性的综述。

Expert Rev Respir Med. 2020 Apr;14(4):353-365. doi: 10.1080/17476348.2020.1718495. Epub 2020 Jan 23.

引用本文的文献

Efficacy Assessment of Biological Treatments in Severe Asthma.重症哮喘生物治疗的疗效评估

J Clin Med. 2025 Jan 7;14(2):321. doi: 10.3390/jcm14020321.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献